Cargando…

Case Report: Semaglutide-associated depression: a report of two cases

Semaglutide, as a glucagon-like peptide-1 receptor agonist (GLP-1 RA), was approved for glucose control in type 2 diabetes mellitus in 2017 and approved for weight loss in 2021 by the U.S. Food and Drug Administration (FDA). No psychiatric adverse effect associated with semaglutide has been reported...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jia-Rui, Cao, Jinya, Wei, Jing, Geng, Wenqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495976/
https://www.ncbi.nlm.nih.gov/pubmed/37706035
http://dx.doi.org/10.3389/fpsyt.2023.1238353

Ejemplares similares